Multiple tools have been developed to predict risk of cognitive decline in PD (Schrag et al., 2017; Dawson et al., 2018; Hogue et al., 2018; Gramotnev et al., 2019; Yousaf et al., 2019; Wilson et al., 2020), however these tools rely on testing not routinely performed outside of tertiary care or research settings (e.g., dopamine transporter (DaT) imaging (Schrag et al., 2017; Yousaf et al., 2019), formal olfactory testing (Schrag et al., 2017), cerebral spinal fluid (CSF) studies (Schrag et al., 2017; Gramotnev et al., 2019; Yousaf et al., 2019), and genetic testing (Gramotnev et al., 2019). The gene discussed is SLC6A3; the disease is Mental deterioration.